[Retracted] Efficacy of TACE+Radiofrequency Ablation+Sorafenib in the Treatment of Patients with Recurrent Liver Cancer and Construction of Prediction Model

Table 3

Univariate analysis of recurrence in two groups [, (%)].

Item	Recurrence group ()	Nonrecurrence group ()	value	value
Age (years)
<60 years	37 (61.67)	18 (60.00)	0.023	0.878
≥60 years	23 (38.33)	12 (40.00)
Gender
Male	36 (60.00)	20 (66.67)	0.378	0.539
Female	24 (40.00)	10 (33.33)
Child-Pugh grade
Grade A	44 (73.33)	17 (56.67)	2.544	0.111
Grade B	16 (26.67)	13 (43.33)
HBV/HCV infection
No	39 (65.00)	14 (46.67)	2.777	0.096
Yes	21 (35.00)	16 (53.33)
PVTT
Yes	52 (86.67)	2 (6.67)	53.33	<0.001
No	8 (13.33)	28 (93.33)
Degree of differentiation
High differentiation	17 (28.33)	4 (13.33)	8.921	0.012
Medium differentiation	28 (46.67)	9 (30.00)
Low differentiation	15 (25.55)	17 (56.67)
Vascular invasion
Yes	28 (46.67)	3 (10.00)	11.908	0.001
No	32 (53.33)	27 (90.00)
Serum AFP level (ng/dl)
<400	22 (36.67)	18 (60.00)	4.410	0.036
≥400	38 (63.33)	12 (40.00)
Number of tumors
Single	27 (54.00)	23 (76.67)	8.122	0.004
Multiple	33 (82.50)	7 (23.33)
Maximum diameter of tumor (cm)
<5	29 (48.33)	22 (73.33)	5.090	0.024
≥5	31 (51.67)	8 (26.67)
Cirrhosis
Yes	24 (40.00)	19 (63.33)	4.364	0.037
No	36 (60.00)	11 (36.67)
Number of nodules
Single nodule	25 (41.67)	20 (66.67)	5.000	0.025
Polynodule	35 (58.33)	10 (33.33)